

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>SETH SANDESH</u> (Last) (First) (Middle) <u>C/O ACTINIUM PHARMACEUTICALS, INC.,</u> <u>100 PARK AVE., 23RD FLOOR</u> (Street) <u>NEW YORK NY 10017</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Actinium Pharmaceuticals, Inc. [ATNM]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Executive Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>03/31/2025</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$59.7 ⁽¹⁾	03/31/2025		D			16,666	(1)	04/15/2026	Common Stock	16,666	\$0 ⁽¹⁾	0	D	
Stock Option (Right to Buy)	\$41.7 ⁽¹⁾	03/31/2025		D			25,000	(1)	03/14/2027	Common Stock	25,000	\$0 ⁽¹⁾	0	D	
Stock Option (Right to Buy)	\$23.49 ⁽¹⁾	03/31/2025		D			33,333	(1)	07/13/2028	Common Stock	33,333	\$0 ⁽¹⁾	0	D	
Stock Option (Right to Buy)	\$6.96 ⁽¹⁾	03/31/2025		D			50,000	(1)	07/12/2029	Common Stock	50,000	\$0 ⁽¹⁾	0	D	
Stock Option (Right to Buy)	\$9.55 ⁽¹⁾	03/31/2025		D			139,062	(1)	08/12/2030	Common Stock	139,062	\$0 ⁽¹⁾	0	D	
Stock Option (Right to Buy)	\$6.07 ⁽¹⁾	03/31/2025		D			310,182	(1)	09/01/2031	Common Stock	310,182	\$0 ⁽¹⁾	0	D	
Stock Option (Right to Buy)	\$4.96 ⁽¹⁾	03/31/2025		D			827,366	(1)	07/01/2032	Common Stock	827,366	\$0 ⁽¹⁾	0	D	
Stock Option (Right to Buy)	\$5 ⁽¹⁾	03/31/2025		D			984,367	(1)	12/28/2033	Common Stock	984,367	\$0 ⁽¹⁾	0	D	

Explanation of Responses:

1. Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value \$0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration.

/s/ Sandesh Seth 04/02/2025
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.